<DOC>
	<DOCNO>NCT01078571</DOCNO>
	<brief_summary>Adalimumab one pharmacological treatment rheumatoid arthritis ( RA ) recent marketing authorization , result , efficacy safety data clinical trial control conditions.The study evaluate safety effectiveness adalimumab common clinical practice RA treatment Spain , several type patient show concomitant treatment diseases compliance . Among tumor necrosis factor antagonists safety study , adalimumab safety less investigated common clinical practice , result recent marketing , include BIOBADASER ( Data Base Biological Products Spain , Rheumatology Spanish Society ) , Biologic Products Database Spanish Society Rheumatology ) determine association infliximab therapy risk develop active tuberculosis . To ensure maintain strict common physician practice ( prescription induction ) , follow recommendation SER ( Sociedad Española de Reumatología , Spanish Society Rheumatology ) consensus document , select patient already treatment adalimumab ( HUMIRA ) , ( except patient involve clinical study Adalimumab ) , show good response , fulfil treatment indication accordance SER recommendation follow Summary Products Characteristics adalimumab ( HUMIRA ) .</brief_summary>
	<brief_title>Safety Effectiveness Adalimumab Patients Diagnosed With Rheumatoid Arthritis</brief_title>
	<detailed_description>Main objective - To evaluate safety tolerability adalimumab ( HUMIRA ) treatment , administer monotherapy combine therapy , rheumatoid arthritis patient usual practice condition . Secondary objective - To evaluate effectiveness adalimumab ( HUMIRA ) treatment , administer monotherapy combine therapy , rheumatoid arthritis patient usual practice condition accordance SER recommendation : - To evaluate life quality associate adalimumab ( HUMIRA ) treatment , administer monotherapy combine therapy , rheumatoid arthritis patient usual practice condition . - To describe profile patient treatment adalimumab ( HUMIRA ) biological therapy .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Patients older 18 year Patients underwent adalimumab treatment least previous 4 month baseline visit , good therapeutic response treatment involve previous clinical study Adalimumab Patients previously baseline visit , prescribe adalimumab comply treatment indication accord SER ( Sociedad Española de Reumatología , Spanish Society Rheumatology ) recommendation : Patients provide informed consent . Patients prescribe adalimumab accord Summary Product Characteristics Patients continue 12 month follow anticipate . The contraindication specify Summary Products Characteristics Hypersensibility component medication administer . Any pathology show patient , accord medical criterion , contraindicate treatment indicate protocol accord Summary Products Characteristics adalimumab ( HUMIRA® ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Biologic</keyword>
	<keyword>Tumor Necrosis Factors blockers agent Monoclonal antibody</keyword>
</DOC>